HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials

Rhea-AI Summary

HTG Molecular Diagnostics (Nasdaq: HTGM) will sponsor a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego on June 16, 2022, at 9:05 AM PT. The presentation, titled “Implementing Biomarker Strategy in Clinical Trials,” will feature Chetan Deshpande from Pfizer, who will discuss how HTG’s EdgeSeq technology addresses clinical trial challenges. HTG focuses on advancing precision medicine through innovative transcriptome-wide profiling to enhance diagnostics and therapeutic strategies.

Positive

• Sponsoring a keynote at a major conference demonstrates HTG's engagement in the life sciences sector.
• Keynote presentation by a Pfizer representative highlights HTG's role in addressing clinical trial challenges.
• HTG's proprietary EdgeSeq technology is being utilized by industry leaders like Pfizer.

Negative

• None.

TUCSON, Ariz., June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be sponsoring a keynote presentation at the 7^th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials” on June 16^th at 9:05 AM PT.

This presentation will feature Chetan Deshpande, Director, Biomarker Clinical Assay Lead, Global Product Development at Pfizer. Mr. Deshpande will discuss the challenges that are generally faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq technology in multiple clinical trials to overcome these challenges.

Details of the Keynote Presentation are below:

Date:	Thursday, June 16th
Time:	9:05 AM PT
Access:	Conference Website

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

HTG Investor Contact:

Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com

FAQ

What is the focus of HTG Molecular Diagnostics?

HTG focuses on advancing precision medicine through transcriptome-wide profiling for diagnostics and targeted therapeutics.

What event is HTG sponsoring?

HTG is sponsoring the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference on June 16, 2022.

Who will present at the HTG-sponsored event?

Chetan Deshpande, Director at Pfizer, will present at the keynote session.

What technology will be discussed in the conference keynote?

The keynote will discuss HTG's EdgeSeq technology and its application in clinical trials.

What is the significance of the keynote presentation for HTG?

The keynote highlights HTG’s contributions to overcoming clinical trial challenges, showcasing its technology's relevance in the industry.